Malignant News and Research

RSS

Blocking cholesterol biosynthesis pathway in cancer cells appears to improve ability of common drugs

Shutting down a specific pathway in cancer cells appears to improve the ability of common drugs to wipe those cells out, according to new research from scientists at Fox Chase Cancer Center, published in the January issue of Cancer Discovery.

16 Jan 2013

Iris nevi have ‘low’ malignant potential

The malignant transformation rate for iris nevi is 8% over 15 years, a case series by US researchers has found.

15 Jan 2013

Aggressive surveillance questionable for eye melanoma recurrence

Patients treated for primary choroidal or ciliary body melanoma may not always benefit from an aggressive surveillance strategy for the detection of metastatic disease, caution US researchers.

14 Jan 2013

Study reports on development and testing of Hematuria Risk Index to predict cancer risk

Microscopic amounts of blood in urine have been considered a risk factor for urinary tract malignant tumors. However, only a small proportion of patients referred for investigation are subsequently found to have cancer. A new Kaiser Permanente Southern California study published in the February Mayo Clinic Proceedings reports on the development and testing of a Hematuria Risk Index to predict cancer risk.

10 Jan 2013

Laryngopharyngeal surgery option for outpatients

Laryngopharyngeal surgeries that are performed in an ambulatory setting demonstrate low complication and admission rates, suggesting that such procedures can be carried out safely on an outpatient basis, show findings from a US study.

8 Jan 2013

Seven scientists named 2013 recipients of Damon Runyon-Rachleff Innovation Award

The Damon Runyon Cancer Research Foundation announced that seven scientists with novel approaches to fighting cancer have been named 2013 recipients of the Damon Runyon-Rachleff Innovation Award.

8 Jan 2013

Merck’s resubmission of the NDA for suggammadex sodium injection accepted for review by the FDA

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the resubmission of the New Drug Application (NDA) for sugammadex sodium injection has been accepted for review by the U.S. Food and Drug Administration (FDA). Merck expects the FDA’s review to be completed in the first half of 2013.

7 Jan 2013

Manipulating T cells with iPSC techniques could help develop effective immune therapies

The human body contains immune cells programmed to fight cancer and viral infections, but they often have short lifespans and are not numerous enough to overcome attacks by particularly aggressive malignancies or invasions.

4 Jan 2013

Ulcerative colitis impairs work capacity

Patients with ulcerative colitis have higher rates of sick leave or disability pension than the general population, show findings published in Gastroenterology.

28 Dec 2012

Juxtapid receives FDA approval for treatment of rare cholesterol disorder

On Dec. 21, the U.S. Food and Drug Administration approved Juxtapid (lomitapide) to reduce low-density lipoprotein (LDL) cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein (non-HDL) cholesterol in patients with homozygous familial hypercholesterolemia (HoFH). Juxtapid is intended for use in combination with a low fat diet and other lipid-lowering treatments.

27 Dec 2012

Cancer-associated inflammation boosts ADAR1 enzyme activity

An international team, headed by researchers at the University of California, San Diego School of Medicine, has identified a key enzyme in the reprogramming process that promotes malignant stem cell cloning and the growth of chronic myeloid leukemia (CML), a cancer of the blood and marrow that experts say is increasing in prevalence.

25 Dec 2012

Computed tomography-induced cancer risk may be overstated

Clinicians should be careful not to overemphasize the risk for radiation-induced cancer when counseling patients on undergoing surveillance computed tomography imaging, caution US scientists.

24 Dec 2012

Comorbidity could alter joint arthroplasty prognosis

The long-term outcome of hip and knee arthroplasty may be significantly influenced by comorbidity, suggest results from a large register-based study of over 96,000 osteoarthritis patients.

22 Dec 2012

New work on Akt's role in cancer stem cell biology

The protein kinase Akt is a key regulator of cell growth, proliferation, metabolism, survival, and death. New work on Akt's role in cancer stem cell biology from the lab of senior author Honglin Zhou, MD, PhD and Weihua Li, co-first author, both from the Center for Resuscitation Sciences, Department of Emergency Medicine, Perelman School of Medicine, University of Pennsylvania, and Xiaowei Xu, Department of Pathology and Laboratory Medicine, appears in Molecular Cell.

21 Dec 2012

Investigators report non-coding miRNAs as appealing biomarkers for cancer malignancy

As many as 50 percent of all human protein-coding genes are regulated by microRNA (miRNA) molecules. While some miRNAs impact onset and progression of cancer, others can actually suppress the development of malignant tumors and are useful in cancer therapy. They can also serve as potential biomarkers for early cancer detection. In a new issue of Cancer Biomarkers, investigators report on non-coding miRNAs as appealing biomarkers for malignancy.

20 Dec 2012

Malignant News and Research

Blocking cholesterol biosynthesis pathway in cancer cells appears to improve ability of common drugs

Iris nevi have ‘low’ malignant potential

Aggressive surveillance questionable for eye melanoma recurrence

Study reports on development and testing of Hematuria Risk Index to predict cancer risk

Laryngopharyngeal surgery option for outpatients

Seven scientists named 2013 recipients of Damon Runyon-Rachleff Innovation Award

Merck’s resubmission of the NDA for suggammadex sodium injection accepted for review by the FDA

Manipulating T cells with iPSC techniques could help develop effective immune therapies

Ulcerative colitis impairs work capacity

Juxtapid receives FDA approval for treatment of rare cholesterol disorder

Cancer-associated inflammation boosts ADAR1 enzyme activity

Computed tomography-induced cancer risk may be overstated

Comorbidity could alter joint arthroplasty prognosis

New work on Akt's role in cancer stem cell biology

Investigators report non-coding miRNAs as appealing biomarkers for cancer malignancy

Enlarged lymph nodes may warn of cancer

PRSS3 enzyme linked to aggressive prostate cancer

Preop features predict pathology of small renal masses

Dantrolene shows promise for treating DMD

Ibrutinib continues to show unprecedented results in patients with mantle cell lymphoma

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News